{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2010"],"condition":["Colorectal Cancer","Colorectal Neoplasms","Cáncer colorrectal avanzado"],"disease":["Colorectal Cancer","Colorectal Neoplasms","Cáncer Colorrectal Avanzado"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2085155"],"location":["Spain"],"study_start_month":["2"],"keyword":["Oxaliplatino","Irinotecan","Capecitabina","Oxaliplatin","5FU","Capecitabine","5-fluorouracilo","Bevacizumab","Fluorouracil"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer","description":"The purpose of the study is to evaluate the efficacy and safety of the capecitabine or 5-fluorouracil selection, according to polymorphisms in TS-3’UTR and ERCC1-118, to be combined with oxaliplatin or irinotecan as first-line chemotherapy in advanced colorectal cancer","dates":{"creation":"2010-02-15"},"accession":"2085155","cross_references":{"ClinicalTrials___gov":["NCT01071655"],"EU Clinical Trials Register":["2009-012562-31"]}}